RPH-051

Phase 3Small molecule

RR-Pharm

RPH-051 is one of 10 small molecule programs targeting Locally Advanced Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Breast CancerActive, not recruiting

Locally Advanced Breast CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

12 competitors in Locally Advanced Breast Cancer

#DrugCompanyPhaseTrials

Herceptin

OOrganon and Co

Phase 3

1 2

Taxotere

AAvyxa

Phase 3

1 3

Gemzar

Johnson & Johnson

Phase 2

1 4

Taxol

Teva

Phase 2

1 5

Halaven

Eisai

Phase 2

1 6

Paraplatin

AAvyxa

Phase 2

1 7

RPH-051

RR-Pharm

Phase 3

1 8

BNT327 Optimized Dose

BioNTech

Phase 2

1 9

DL2

Sun Pharma Advanced Research Company Limited

Phase 2

1 10

BNT327

BioNTech

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Active, not recruiting

Locally Advanced Breast Cancer

NCT07386938

Clinical

Trials by Indication[1]

Locally Advanced Breast Cancer1 trial

International, Multicenter, Double-blind, Randomized, Comparative Study of Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® Drug Products Combined With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Metastatic or Locally Recurrent Unresectable Breast Cancer

Active, not recruiting·RR-Pharm·Phase 3·NCT07386938·246 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RPH-051. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RPH-051 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RPH-051. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — R-Pharm company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RR-Pharm

RPH-051

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Locally Advanced Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News